Boston Scientific: EuroPCR: Highlights from our 1x1 with Boston’s President of Cardiovascular

Research evidence excerpt

Boston Scientific: EuroPCR: Highlights from our 1x1 with Boston’s President of Cardiovascular

Deutsche Bank

Research

Rating Company Date

Buy Boston Scientific 21 May 2026

Company Update

North America

United States

Reuters Bloomberg Exchange Ticker Price at 19 May 2026 (USD) 56.81

BSX.N BSX US NYS BSX

Price Target 75.00

Health Care

52-week range 108.14 - 52.68

Medical Supplies & Devices

EuroPCR: Highlights from our 1x1 with

Valuation & Risks Boston’s President of Cardiovascular

Pito Chickering

Portfolio Manager Summary Research Analyst

We had the opportunity to sit down with Joe Fitzgerald, President of Boston’s +1-917-635-9954

Cardiovascular group of businesses that account for two-thirds of total company

Imron Zafar

sales, today at the ongoing EuroPCR meeting in Paris. While the near-term Street Research Analyst

focus remains squarely on the duo of blockbuster AF therapies (LAAO and PFA), our +1-212-250-3676

discussion centered mostly around the myriad other product/pipeline categories

Kieran Ryan

within CV that we believe will be increasingly growth contributory over the LRP

Research Associate

period, including IVL, renal denervation, and coronary DCB among others. So while

+1-212-250-6879

we expect that growth/share trends for Watchman and Farapulse will remain most

determinative of BSX share performance nearer term, we are increasingly positive Ben Shaver

on the growth outlook for these and other CV products over the forecast period. Research Associate

+1-212-250-9926

Intravascular lithotripsy (IVL)

As highlighted in our prior note, late-breaker FRACTURE trial results for Boston’s

Seismiq IVL catheter in vessel prep in moderate-to-severe coronary artery

calcification were positive and should be supportive of meaningful share capture in